Sigyn Therapeutics, Inc.
SIGY
$4.10
-$0.0099-0.24%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 40.86% | 2.11% | 6.43% | 51.59% | 6.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.78% | 5.02% | 20.85% | 52.08% | 20.46% |
| Operating Income | -25.78% | -5.02% | -20.85% | -52.08% | -20.46% |
| Income Before Tax | -32.15% | -19.26% | 43.47% | -36.93% | -24.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -32.15% | -19.26% | 43.47% | -36.93% | -24.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.15% | -19.26% | 43.47% | -36.93% | -24.67% |
| EBIT | -25.78% | -5.02% | -20.85% | -52.08% | -20.46% |
| EBITDA | -25.89% | -5.25% | -21.17% | -53.01% | -20.53% |
| EPS Basic | -15.19% | -4.34% | 55.81% | -3.30% | -5.11% |
| Normalized Basic EPS | -15.18% | 19.01% | 56.33% | -34.30% | -5.11% |
| EPS Diluted | -15.05% | -4.48% | 55.54% | -5.95% | -2.50% |
| Normalized Diluted EPS | -15.18% | 19.01% | 56.33% | -34.30% | -5.11% |
| Average Basic Shares Outstanding | 14.74% | 14.29% | 27.95% | 32.53% | 18.60% |
| Average Diluted Shares Outstanding | 14.74% | 14.29% | 27.95% | 32.53% | 18.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
